
Is Puma Biotechnology (PBYI) stock Halal?
As of the September 2026 screening, Puma Biotechnology, Inc. (PBYI) meets every AAOIFI Shariah Standard No. 21 requirement: non-permissible income, interest-bearing investments and interest-bearing debt all sit within the thresholds, and there is no impermissible preference share structure. The dividend purification factor is 98.55%. The stock is re-screened every month.
Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies aimed at treating cancer. Its primary focus centers on enhancing cancer treatment through advanced pharmaceutical interventions, particularly targeting breast cancer and other tumors that overexpress the HER2 protein. A key product in Puma Biotechnology's portfolio is neratinib, an oral medication designed to inhibit cancer cell proliferation by interfering with the HER2/neu and EGFR kinases. For Muslim investors, though, the most pressing question is simpler: is Puma Biotechnology a Halal investment?
Is Puma Biotechnology Shariah compliant?
Technology companies rarely fail AAOIFI screening on what they sell. Software, hardware and digital services are permissible business activities, so for a company like Puma Biotechnology the Shariah question moves to the balance sheet: how much of its market value sits in interest bearing debt, how much of its cash earns Riba in conventional deposits, and whether incidental income from impermissible sources creeps past 5% of revenue. These are exactly the ratios AAOIFI Shariah Standard No. 21 polices, and they move every month with the share price.
Does Puma Biotechnology pass the business activity test?
Yes. In the September 2026 screening Puma Biotechnology holds an overall PASS, which a stock only earns when its core business clears the activity screen. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.
Is Puma Biotechnology's income Halal?
Yes, within AAOIFI's tolerance. Puma Biotechnology's income from non-permissible sources stays below 5% of revenue in the September 2026 screening, and the small impure portion is handled through purification: the factor of 98.55% tells holders of PBYI what share of each dividend to keep and what remainder to donate to charity.
Does Puma Biotechnology meet AAOIFI's debt and investment ratio requirements?
Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation. Because the caps move with the share price, our Shariah Supervisory Board has PBYI re-screened every month, and the result above always shows the latest verdict.
Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.
New to the four screens? Read Why a Halal Stock Screener Matters for Halal Investing



